康泰醫學(300869.SZ):9名董監高共完成減持403.83萬股
格隆匯12月31日丨康泰醫學(300869.SZ)公佈,2021年12月31日,公司分別收到董事、高管楊志山、鄭敏,監事高瑞斌、李學勇、陳克權、楊波、呂揚,高管劉振紅分別出具的《關於減持計劃實施完畢的吿知函》,高管許雲龍出具的《關於股份減持計劃實施進展暨提前終止減持計劃的吿知函》,截至目前,楊志山、鄭敏、高瑞斌、李學勇、陳克權、楊波、呂揚、劉振紅披露減持股份計劃均已實施完畢,許雲龍提前終止減持計劃。
其中,楊志山、鄭敏、高瑞斌、劉振紅、許雲龍於2021年9月24日-12年29日通過集中競價方式合計減持公司股份366.87萬股;李學勇、陳克權、楊波、呂揚於2021年10月8日-12月29日通過康泰投資間接減持合計36.96萬股
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.